Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Libtayo (cemiplimab-rwlc) for the Treatment of CSCC

CSCC accounts for approximately 20% of all skin cancers in the US. Image courtesy of LWozniak&KWZielinski.

  • Libtayo
  • Libtayo
  • Libtayo

Go Top